Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME study of [14C] PBI-200 in healthy male subjects
NCT05238337Phase 1Completed
- Sponsor
- Pyramid Biosciences
- Start
- Feb 2022
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paltimatrectinib in NTRK fusion-positive solid tumors, sponsored by Pyramid Biosciences. Primary endpoints: Total Radioactivity in Urine and Feces at 28 days, Area Under the Concentration-Time Curve from time zero to infinity at 28 days and 7 more. Started Feb 2022; status: completed.
02
Drugs
paltimatrectinib
03
Conditions
NTRK fusion-positive solid tumors
Beyond the preview
Go deeper on NCT05238337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05238337.